MPN Research
The concept of myeloproliferative disorders (MPNs) was first described in 1951 by Dr. William Dameshek, the preeminent American clinical hematologist of his time.
​
Since then, great strides have been made in our understanding of these disorders and in the development of new treatment options. And the research continues to evolve ...
​
MPN Research Milestones:
-
1999: The first clinical trial for myeloproliferative disorders, “Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders” is initiated.
​
-
2003: The MPD Research Consortium is created to serve as a multi-institution, international group dedicated to establishing clinical trials and conducting basic research into new therapies and treatments.
​
-
2005: The JAK2V617F mutation is discovered. JAK2 is the first known genetic mutation associated with myeloproliferative diseases.
​
-
2008: Myeloproliferative disorders are reclassified as myeloproliferative neoplasms (MPNs) by the World Health Organization and nested within the blood cancer category.
​
-
2011: The first FDA-approved treatment for myelofibrosis, Jakafi, is released.
​
-
2013: Calreticulin (CALR) is discovered – a second significant genetic mutation that accounts for the majority of JAK2 negative patients.